Business
SCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update
Oral ibrexafungerp continues to advance in multiple indicationsNearing completion of Phase 3 VANISH program, evaluating oral ibrexafungerp for the treatment
About this update from Scynexis, Inc.
[{"type":"text","content":"Oral ibrexafungerp continues to advance in multiple indicationsNearing completion of Phase 3 VANISH program, evaluating oral ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC), more commonly known as vaginal yeast infection; second of two studies (VANISH-306) has completed enrollment in the U.S. and Europe; anticipate top-line data early second quarter 2020 with NDA submission in second half of 2020Enrollment is ongoing in Phase 3 CANDLE study of oral ibrexafungerp for the prevention of recurrent vaginal yeast infections; anticipate top-line data and supplemental NDA submission in second half of 2021Enrollment continues in Phase 3 refractory invasive fungal infections (rIFI) program (FURI and CARES studies) of oral ibrexafungerp in severe and difficult-to-treat fungal infections, including multidrug-resistant Candida auris; recently expanded FURI study protocol JERSEY CITY, N.J., March 11, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug resistant infections, reported financial results for the year ended December 31, 2019, and provided an update on recent clinical and corporate developments.\n \"The significant progress made in 2019 advanced us several steps closer to our goal of bringing ibrexafungerp to millions of patients worldwide who are in need of new options to overcome and prevent serious fungal infections. We are conducting multiple late-stage clinical studies of oral ibrexafungerp in indications ranging from vaginal yeast infections, for which there’s only one approved oral therapy, to the life-threatening Candida auris infections affecting patients in hospital settings with compromised immune systems,” said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. \"Ibrexafungerp represents a novel class of antifungals in a field in which no new class has been approved in nearly 20 years. We believe ibrexafungerp has the potential to become a leading antifungal therapy in both the community and hospital settings, particularly given the lack of innovation in the category, growing resistance to existing treatments, and evolution of new species that pose an urgent threat to the public.\" Ibrexafungerp Development Update Announced positive top-line results for the Phase 3 VANIS...